Epigenetics in Myeloproliferative Neoplasms. Issue 9 (4th July 2017)

• Record Type: Journal Article
• Authors: McPherson, Suzanne; McMullin, Mary Frances; Mills, Ken
• Is Part Of: Journal of cellular and molecular medicine. Volume 21:Issue 9(2017)
• Page Start: 1660
• Page End: 1667
• Publication Date: 2017-07-04
• Subjects: myeloproliferative neoplasm -- epigenetics -- cell signalling -- janus kinase -- DNA methylation -- histone modification -- miRNA regulation -- combination epigenetic therapy; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13095
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: A decade on from the description of JAK2 V617F, the MPNs are circumscribed by an increasingly intricate landscape. There is now evidence that they are likely the result of combined genetic dysregulation, with several mutated genes involved in the regulation of epigenetic mechanisms. Epigenetic changes are not due to a change in the DNA sequence but are reversible modifications that dictate the way in which genes may be expressed (or silenced). Among the epigenetic mechanisms, DNA methylation is probably the best described. Currently known MPN‐associated mutations now include JAK2, MPL, LNK, CBL, CALR, TET2, ASXL1, IDH1, IDH2, IKZF1 and EZH2 . Enhancing our knowledge about the mutation profile of patients may allow them to be stratified into risk groups which would aid clinical decision making. Ongoing work will answer whether the use of epigenetic therapies as alterative pathway targets in combination with JAK inhibitors may be more effective than single agent treatment.